Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France (GYDECAT)

November 14, 2025 updated by: Centre Hospitalier Universitaire de Nīmes

Gynecology Beyond Gender: Exploration and Identification of Potential Obstacles and Levers in France for Cervical Cancer Screening in Transgender Men, by Conducting an Opinion Survey in a Specific Population

In France, cervical cancer screening is the subject of a national screening programme organized for all asymptomatic individuals aged 25 to 65 years with a cervix. The latter contributes greatly to the prevention and early treatment of this disease, whose public health challenge is recognized worldwide.

One of the objectives of this programme is to reduce inequalities in access. Transgender men, i.e. individuals assigned to the female gender at birth but identifying with the male gender, are concerned by this screening as long as they still have a cervix, according to the same modalities as for cisgender women.

However, they are often excluded from health care, including organized screening programs. Gender change in civil status is one of the obstacles.

The provision of gynaecological care is sometimes inadequate. The lack of knowledge of health professionals and the problems of discrimination that transgender people may face reduce the chances of having equitable access.

This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Nîmes, France, 30900
        • CHU de Nîmes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Transgender men, i.e. individuals assigned the female gender at birth but identifying with the male gender, who retained the cervix

Description

Inclusion Criteria:

  • transgender male (assigned female at birth but identifying as male)
  • aged 25 to 65 years
  • Having retained her cervix
  • Having had sex before.

Exclusion Criteria:

  • Under 25 and over 65
  • Not having retained his cervix
  • History of cancerous lesion of the cervix

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
prevalence of transgender men who have ever been screened for cervical cancer in their lifetime
Time Frame: At study entry, basline (no follow-up)
answer yes to the question "Have you ever been screened for cervical cancer in your lifetime?"
At study entry, basline (no follow-up)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
prevalence of transgender men who feel concerned about cervical cancer screening
Time Frame: At study entry, basline (no follow-up)
answer yes to the question "Do you feel personally involved in cervical cancer screening?"
At study entry, basline (no follow-up)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Nīmes

Investigators

  • Principal Investigator: ingrid JULIER, Centre Hospitalier Universitaire de Nîmes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 2, 2024

Primary Completion (Actual)

January 1, 2025

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

June 12, 2023

First Submitted That Met QC Criteria

June 20, 2023

First Posted (Actual)

June 29, 2023

Study Record Updates

Last Update Posted (Actual)

November 17, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LOCAL/2023/thése/IJ-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe